Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.

Lloyd A, Penson D, Dewilde S, Kleinman L
Prostate Cancer Prostatic Dis. 2008 11 (2): 153-9

PMID: 17637761 · DOI:10.1038/sj.pcan.4500992

Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.

MeSH Terms (25)

Adenocarcinoma Aged Androgen Antagonists Anilides Antineoplastic Agents, Hormonal Choice Behavior Cross-Sectional Studies Diarrhea Drug Administration Schedule Drug Costs Drug Therapy Erectile Dysfunction Flutamide Gynecomastia Health Surveys Hematuria Humans Life Expectancy Male Middle Aged Nitriles Patient Acceptance of Health Care Patient Satisfaction Prostatic Neoplasms Tosyl Compounds

Connections (1)

This publication is referenced by other Labnodes entities: